First pharmacophoric hypothesis for 5-HT7 antagonism

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 10, 2000, Pages 1097-1100

  López Rodríguez, María L ^a   Porras, Esther ^a   Benhamú, Bellinda ^a   Ramos, José A ^a   Morcillo, M José ^b   Lavandera, José L ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD NACIONAL DE EDUCACIÓN A DISTANCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

NAPHTHOLACTAM DERIVATIVE; NAPHTHOSULTAM DERIVATIVE; SEROTONIN 7 RECEPTOR; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

ARTICLE; BRAIN MEMBRANE; DRUG ANTAGONISM; DRUG STRUCTURE; DRUG SYNTHESIS; HYPOTHALAMUS; MOLECULAR MODEL; NONHUMAN; PHARMACOPHORE; RAT;

ANIMALS; CELL MEMBRANE; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HYPOTHALAMUS; MODELS, MOLECULAR; RATS; RECEPTORS, SEROTONIN; REPRODUCIBILITY OF RESULTS; SEROTONIN ANTAGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0343673400     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00166-9     Document Type: Article

References (24)

1. Rapport M.M., Green A.A., Page I.H. Fed. Proc. 6:1947;184.
2. (a) In Serotoninergic Neurons and 5-HT Receptors in the CNS; Baumgarten, H. G.; Göthert, M., Eds.; Springer-Verlag: Berlin, 1997.
3. (b) Uphouse, L. Neurosci. Biobehav. Rev. 1997, 21, 679.
4. Eglen R.M., Jasper J.R., Chang D.J., Martin G.R. Trends Pharmacol. Sci. 18:1997;104.
5. (a) Yau, J. L. W.; Noble, J.; Widdowson, J.; Seckl, J. R. Mol. Brain Res. 1997, 45, 182.
6. (b) Shimizu, M.; Nishida, A.; Zensho, H.; Yamawaki, S. J. Pharmacol. Exp. Ther. 1996, 279, 1551.
7. Ying S.-W., Rusak B. Brain Res. 755:1997;246.
8. (a) Terrón, J. A.; Falcon-Neri, A. Br. J. Pharmacol. 1999, 127, 609.
9. (b) De Vries, P.; De Visser, P. A.; Heiligers, J. P. C.; Villalón, C. M.; Saxena, P. R. Naunyn-Schmiedeberg's Arch. Pharmacol. 1999, 359, 331.
10. Forbes I.T., Dabbs S., Duckworth D.M., Jennings A.J., King F.D., Lovell P.J., Brown A.M., Collin L., Hagan J.J., Middlemiss D.N., Riley G.J., Thomas D.R., Upton N. J. Med. Chem. 41:1998;655.
11. Kikuchi C., Nagaso H., Hiranuma T., Koyama M. J. Med. Chem. 42:1999;533.
12. Lovell P.J., Bromidge S.M., Dabbs S., Duckworth D.M., Forbes I.T., Jennings A.J., King F.D., Middlemiss D.N., Rahman S.K., Saunders D.V., Collin L.L., Hagan J.J., Riley G.J., Thomas D.R. J. Med. Chem. 43:2000;342.
13. catalyst 3.1; Molecular Simulations Inc.: San Diego, CA, 1996.
14. (a) Plassat, J. L.; Amlaiky, N.; Hen, R. Mol. Pharmacol. 1993, 44, 229.
15. (b) Hirst, W. D.; Price, G. W.; Rattray, M.; Wilkin, G. P. Br. J. Pharmacol. 1997, 120, 509.
16. (c) McLean, P. G.; Coupar, I. M. Eur. J. Pharmacol. 1996, 312, 215.
17. Shen Y., Monsma F.J. Jr., Metcalf M.A., Jose P.A., Hamblin M.W., Sibley D.R. J. Biol. Chem. 268:1993;18200.
18. To Z.P., Bonhaus D.W., Eglen R.M., Jakeman L.B. Br. J. Pharmacol. 115:1995;107.
19. Bard, J. A; Zgombick, J.; Adham, N.; Vaysse, P.; Branchek, T. A.; Weinshank, R. L. J. Biol. Chem. 1993, 268, 23422.
20. Ruat M., Traiffort E., Leurs R., Tardivel-Lacombe J., Diaz J., Arrang J.-M., Schwartz J.-C. Proc. Natl. Acad. Sci. USA. 90:1993;8547.
21. Jasper J.R., Kosaka A., To Z.P., Chang D.J., Eglen R.M. Br. J. Pharmacol. 122:1997;126.
22. th EFMC International Symposium on Medicinal Chemistry, Edinburgh, 6-10 September 1998, p 339.
23. 2:hexane).
24. Aguirre N., Ballaz S., Lasheras B., Del Río J. Eur. J. Pharmacol. 346:1998;181.